An Assessment of Statin Safety by Hepatologists
Review
Overview
MeSH Major
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Liver Failure
abstract
The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association's (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.
